Economic information and modeling report
Modeling overview
37 evidence topics · 29 sources
Summary: comparator prices, payer criteria, ICER assessment, published economic evaluations, and utility weights
No price, cost-effectiveness analysis, or budget impact analysis of lanifibranor was identified. Inventiva states that market acceptance of lanifibranor “will depend significantly on the availability of coverage and adequate reimbursement from third-party payors”.
The two approved comparators for noncirrhotic MASH with F2 to F3 fibrosis have these published prices. Resmetirom (Rezdiffra) has a wholesale acquisition cost of $4,239.38 per 30-tablet package for each strength (60, 80, and 100 mg) as of October 1, 2026, and was reported at a launch annual wholesale acquisition cost of $47,400 in March 2024. Semaglutide 2.4 mg (Wegovy) has a list price of $1,349.02 per package; Novo Nordisk announced on February 24, 2026 that the list price of Wegovy will be lowered to $675, effective January 1, 2027, a reduction of approximately 50%.
Five payer policies were reviewed (Cigna, Prime Therapeutics HCSC, Aetna, PA Health and Wellness, Alaska Medicaid). Each requires F2 or F3 fibrosis confirmed by liver biopsy or noninvasive testing, with biopsy look-back periods of 12 months to 3 years where one is stated, and Cigna, Aetna, and PA Health and Wellness require prescribing by or in consultation with a specialist. Prime Therapeutics HCSC requires an inadequate response after 72 weeks of semaglutide, or one of its listed exceptions, before resmetirom, and PA Health and Wellness requires a 6-month semaglutide trial in members without F3 fibrosis. ICER's 2023 policy recommendations state that liver biopsy should not be universally required for diagnosis and that step therapy requiring prior pioglitazone or vitamin E is not reasonable.
ICER's May 2023 assessment rated resmetirom “C++” compared with standard of care in NASH with F2 or F3 fibrosis. Its lifetime Markov model (health care sector perspective, annual cycles) used utilities of 0.76 for fibrosis stages F0 to F2 and 0.73 for F3, derived from the GAIN study, and annual costs of $7,063 and $8,423 for those states, based on US estimates from the GAIN study (2022 US dollars). At a placeholder price of $19,000 per year, resmetirom produced lifetime savings of approximately $22,400 and approximately 0.60 QALYs gained. The health-benefit price benchmark for resmetirom was $39,600 to $50,100. ICER applied a prevalence of 1.4% to US adults, assumed 762,119 treatment initiators per year, found that 6.5% of eligible patients could be treated at the placeholder price before reaching its budget impact threshold of approximately $777 million per year, and issued an access and affordability alert.
Published US cost-effectiveness analyses of the approved comparators report these incremental cost-effectiveness ratios (the first three against standard of care): semaglutide $42,200 and resmetirom $95,981 per QALY at 5 years (US payer perspective); semaglutide 2.4 mg $19,911, resmetirom 80 mg $346,810, and resmetirom 100 mg $198,607 per QALY over a lifetime (model developed under contract with Novo Nordisk); tirzepatide $42,705, semaglutide $80,076, and resmetirom $273,445 per QALY over a lifetime, using annual treatment costs of $59,268.96 for resmetirom and $16,188.24 for semaglutide; and resmetirom $53,929 per QALY in an early Madrigal-funded analysis. A cost-utility analysis of pioglitazone and vitamin E in NASH with fibrosis level 3 or greater reported $A2748 and $A8475 per QALY gained compared with lifestyle modification alone. Noninvasive-test screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis in the model, ranged from $23,265 to $27,884 per QALY.
A Madrigal-funded budget impact analysis for a hypothetical one-million-member US private plan estimated 50 to 238 patients treated with resmetirom over years 1 to 3, a net budget impact of $2.2 to $9.5 million, and $0.19 to $0.80 per member per month. A Madrigal-funded calculator estimated 1,255 to 1,699 treatment-eligible adults per 1 million commercial members in years 1 to 3, and an NHANES 2017 to March 2020 analysis estimated 8.3 million (liberal criteria) and 2.3 million (restrictive criteria) US adults meeting resmetirom eligibility criteria.
Published utility weights by fibrosis stage include mean EQ-5D indices of 0.80 (F0 to F2) and 0.67 (F3 to F4) in US respondents of the GAIN study, discrete choice experiment-derived values of 0.671 (MASH F2) and 0.605 (MASH F3) used as model inputs, and a mapped EQ-5D utility of approximately 0.78 at baseline in ESSENCE.
Resmetirom (Rezdiffra) wholesale acquisition cost per 30-tablet package, October 2026
| Marketed product | WAC package | Package size |
|---|---|---|
| Rezdiffra 60 mg | “$4,239.38” | “30” |
| Rezdiffra 80 mg | “$4,239.38” | “30” |
| Rezdiffra 100 mg | “$4,239.38” | “30” |
Resmetirom annual wholesale acquisition cost at launch, March 2024, superseded by January 2026
Semaglutide 2.4 mg (Wegovy) list price per package
Semaglutide (Wegovy) list price of $675 per month scheduled for January 2027, announced February 2026
Payer coverage: Cigna National Formulary prior authorization criteria for resmetirom, April 2026
Payer coverage: Prime Therapeutics HCSC resmetirom criteria with a semaglutide (Wegovy) step, November 2026
Payer coverage: Aetna non-Medicare prior authorization criteria for semaglutide (Wegovy injection) in noncirrhotic MASH, August 2026 policy
Payer coverage: PA Health and Wellness resmetirom criteria requiring a semaglutide (Wegovy) trial in members without F3 fibrosis, October 2025
Payer coverage: Alaska Medicaid prior authorization criteria for resmetirom, effective June 2026
“ALASKA MEDICAID” (opens the source at this quote in a new tab)
“Effective: 6/1/2026” (opens the source at this quote in a new tab)
“Magnetic resonance elastography (MRE) score >2.6” (opens the source at this quote in a new tab)
“Enhanced liver fibrosis (ELF) score >7.7 AND;” (opens the source at this quote in a new tab)
“Patient Fibrosis 4 index (FIB-4) score ≥ 1.3 AND;” (opens the source at this quote in a new tab)
“Initial Approval: up to 3 months” (opens the source at this quote in a new tab)
“Reauthorization: up to 12 months” (opens the source at this quote in a new tab)
ICER coverage policy recommendations for NASH therapies, May 2023
ICER evidence rating for resmetirom compared with standard of care, May 2023
ICER cost-effectiveness model: structure, perspective, and time horizon
ICER cost-effectiveness model: health-state utilities by fibrosis stage
| Health state | Base case | Lower value | Upper value |
|---|---|---|---|
| NASH fibrosis stage 0 to 2 | “0.76” | “0.61” | “0.91” |
| NASH fibrosis stage 3 | “0.73” | “0.64” | “0.82” |
| Compensated cirrhosis | “0.66” | “0.49” | “0.83” |
| Decompensated cirrhosis | “0.57” | “0.46” | “0.68” |
| Hepatocellular carcinoma | “0.50” | “0.40” | “0.60” |
| Liver transplantation (year of) | “0.66” | “0.49” | “0.83” |
| Post-liver transplantation | “0.73” | “0.64” | “0.82” |
| Disutility: myocardial infarction event | “-0.041” | “-0.041” | “-0.041” |
| Disutility: stroke event | “-0.052” | “-0.053” | “-0.052” |
ICER cost-effectiveness model: annual non-drug costs by health state, 2022 US dollars
| Health state | Base case | Lower value | Upper value |
|---|---|---|---|
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |
| Liver transplant procedure | “$232,674” | “$186,140” | “$279,209” |
| Post liver transplant procedure | “$43,358” | “$34,686” | “$52,030” |
ICER cost-effectiveness model: resmetirom placeholder price
ICER cost-effectiveness model: base-case results for resmetirom at the placeholder price, health care sector perspective
| Treatment | Drug cost | Total cost | QALYs | evLYs | Life years |
|---|---|---|---|---|---|
| Resmetirom (placeholder price) | “$76,000” | “$416,000” | “10.66” | “10.74” | “15.05” |
| Standard care | “$0” | “$439,000” | “10.05” | “10.05” | “14.56” |
ICER threshold prices and health-benefit price benchmark for resmetirom
ICER potential budget impact: eligible US adults, uptake, and access and affordability alert
ICER report status: 18-month stakeholder request, January 2025
Published cost-effectiveness analysis: semaglutide and resmetirom compared with standard of care in MASH with F2 to F3 fibrosis, US payer perspective, 5- and 10-year horizons
“A state-transition model simulated disease progression in a hypothetical cohort with F2–F3 fibrosis over 5- and 10-year horizons from a U.S. healthcare payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide was cost-effective versus SOC at 5 years (ICER, $42,200/QALY) and 10 years (ICER, $44,138/QALY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resmetirom produced higher ICERs ($95,981/QALY at 5 years; $107,002/QALY at 10 years) but remained below a $150,000/QALY threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a 10-year horizon, treatment of 100,000 patients with F2–F3 MASH was projected to prevent 270 cases of decompensated cirrhosis, 10 cases of hepatocellular carcinoma, and 1,040 liver-related deaths with semaglutide, compared with 310 cases of decompensated cirrhosis, 10 cases of hepatocellular carcinoma, and 1,180 liver-related deaths with Resmetirom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-effectiveness analysis: semaglutide 2.4 mg and resmetirom compared with standard of care, US third-party payer perspective, lifetime horizon, Novo Nordisk-funded
“Cost effectiveness was assessed from a United States (US) third-party payer perspective. The impact of semaglutide 2.4 mg on quality-adjusted life years (QALYs), cost, and clinical outcomes was simulated over a lifetime horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were adjusted to 2025 US dollars. Costs and health outcomes were discounted at 3% annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the cost-effectiveness analysis, semaglutide 2.4 mg had an incremental cost-effectiveness ratio of US$19,911 per QALY gained compared with SoC, while corresponding incremental cost-effectiveness ratios were US$346,810 for resmetirom 80 mg and US$198,607 for resmetirom 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a scenario analysis that used the direct-to-consumer cash price for semaglutide 2.4 mg (US$499 per month), semaglutide 2.4 mg was less costly and more effective than SoC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These utilities were taken from the Institute for Clinical and Economic Review 2023 NASH assessment, which sourced fibrosis stage values from the GAIN study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FC is an employee of Genesis Research Group (Hoboken, NJ), which was contracted by Novo Nordisk Inc., Plainsboro, NJ, USA to develop the model and manuscript.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-effectiveness analysis: resmetirom, semaglutide, and tirzepatide compared with standard of care in MASH with F2 to F3 fibrosis, US payer perspective, lifetime horizon, with model inputs
“We evaluated the cost-effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2-F3 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We developed a Markov cohort model with a lifetime horizon from the perspective of a U.S. healthcare payer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base-case analysis, tirzepatide had the largest QALY gain and the lowest incremental cost relative to standard of care, yielding an incremental cost-effectiveness ratio of ($42 705/QALY). Semaglutide was also cost-effective (ICER: $80 076/QALY). Resmetirom (ICER: $273 445/QALY) exceeded the WTP threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug price was the most influential parameter in sensitivity analyses” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All drug prices used in the model reflect wholesale acquisition cost (WAC) values as listed by the manufacturers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stage‐specific utilities for MASH and fibrosis F1 through decompensated cirrhosis were taken from a primary EQ‐5D‐5L and discrete choice experiment elicitation study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published early cost-effectiveness analysis of resmetirom, US commercial payer perspective, Madrigal-funded
“This early analysis explored the potential cost effectiveness of resmetirom for the treatment of NASH from a US commercial payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resmetirom treatment resulted in increased costs of US$66,764 per patient, while increasing QALYs by 1.24. The incremental cost-effectiveness ratio was US$53,929 per QALY gained” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resmetirom treatment remained cost effective at a US$100,000 WTP threshold up to a daily price point of US$72.00.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Madrigal Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Model input | Base-case value |
|---|---|
| Cost of resmetirom, oral, 100 mg daily (US$) | “U.S.$52.05”View highlighted excerpt for this quote |
Published cost-utility analysis: pioglitazone and vitamin E in biopsy-proven NASH with fibrosis level 3 or greater, third-party payer perspective, costs in Australian dollars ($A)
“Using a third-party payer perspective, a deterministic Markov model was developed to compare costs and health benefits of lifestyle modification alone or with pioglitazone or vitamin E in a cohort of patients aged 50 years with biopsy-proven NASH and fibrosis level 3 or greater.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In comparison with lifestyle modification alone, treatment with either pioglitazone or vitamin E in addition to lifestyle modification was cost-effective, with incremental cost-effectiveness ratios of $A2748 and $A8475 per quality-adjusted life year (QALY) gained, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Published cost-utility analysis: noninvasive-test screening strategies for high-risk MASLD in US primary care, including resmetirom treatment of F2 or F3 fibrosis
“All screening strategies for high-risk MASLD in US incurred additional costs compared to no screening” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model included treatment effects of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24 992 per QALY for patients with obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Published generalized cost-effectiveness analysis: screening and treatment of MASH in people with type 2 diabetes, 12 countries including the United States
“This economic evaluation consisted of a generalized cost-effectiveness analysis (GCEA) that was conducted for 12 countries (Brazil, Chile, Germany, Italy, Japan, Saudi Arabia, South Africa, Spain, Sweden, Tanzania, Thailand, and the United States), across all 6 World Health Organization (WHO) regions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with intensive lifestyle interventions (ILIs), after screening via ELF or VCTE, was cost-effective in all countries. ILIs and treatment with semaglutide was cost-effective in 11 countries (not in Tanzania); ILIs and treatment with resmetirom was cost-effective in 8 countries (not in Brazil, South Africa, Tanzania, or Thailand).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Published US disease burden model: hypothetical therapy that halts fibrosis progression
“The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact analysis: resmetirom in a hypothetical one-million-member US private health plan over 3 years, Madrigal-funded
Eligible population per 1 million US commercial members: diagnosed adults with noncirrhotic NASH and F2 to F3 fibrosis, Madrigal-funded calculator
“adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis (MALF) consistent with stages F2/F3 fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base case, a NASH prevalence of 4.6% was modeled (range 1.3-14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Published analyses suggest a diagnosis rate of ~ 10% (range 3.3-14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255-1699 in Years 1-3 following approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Design, study conduct, and financial support (including the journal’s Rapid Service Fee and Open Access Fee) for the study were provided by Madrigal Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligible population: US adults meeting resmetirom eligibility criteria, NHANES 2017 to March 2020
“A cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES) 2017-March 2020 cycle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An estimated 8.3 million (95% CI: 6.6-9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4-3.2 million) met the restrictive criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility weights: EQ-5D by early (F0 to F2) and advanced (F3 to F4) fibrosis in biopsy-confirmed NASH, GAIN study, Europe and the United States
“The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean EQ-5D and CLDQ-NAFLD index scores were 0.75 and 4.9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| EQ-5D index, mean (SD) | Early (F0 to F2) | Advanced (F3 to F4) | Overall |
|---|---|---|---|
| United States | “0.80 (0.19)”View highlighted excerpt for this quote | “0.67 (0.23)”View highlighted excerpt for this quote | “0.75 (0.22)”View highlighted excerpt for this quote |
| All countries | “0.80 (0.2)”View highlighted excerpt for this quote | “0.62 (0.33)”View highlighted excerpt for this quote | “0.75 (0.26)”View highlighted excerpt for this quote |
Health-state utility weights: EQ-5D estimated from CLDQ-NAFLD and SF-36 in noncirrhotic MASH
“Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility weights: discrete choice experiment by fibrosis stage, UK general public and patients with NASH, Boehringer Ingelheim-funded
“DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Financial support for this study was provided by a contract with Boehringer Ingelheim International GmbH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility weights: mapped EQ-5D at baseline and week 72 with semaglutide 2.4 mg in MASH with F2 or F3 fibrosis, ESSENCE, Novo Nordisk-sponsored
“This exploratory analysis used Week 72 data from ESSENCE Part 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline mapped EQ-5D utility was approximately 0.78 in both groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 72, semaglutide significantly improved mapped EQ-5D utility vs. placebo (estimated treatment difference 0.03; 95% CI 0.01-0.06; nominal p = 0.0015), with consistent effects across fibrosis stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by Novo Nordisk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility weights: SF-6D in noncirrhotic and cirrhotic NAFLD
Lanifibranor: Inventiva statements on coverage, reimbursement, and cost-effectiveness data
Lanifibranor price, cost-effectiveness analysis, or budget impact analysis
No evidence found.